Cited 1 times in
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상학 | - |
dc.date.accessioned | 2024-03-22T05:40:55Z | - |
dc.date.available | 2024-03-22T05:40:55Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198143 | - |
dc.description.abstract | Purpose There are few studies in the literature on the dosage of statin that equivalently reduces low-density lipoprotein cholesterol (LDL-C) compared to an ezetimibe combination and whether such regimens have differences in safety. We compared the lipid-modifying efficacy and safety of 5 mg rosuvastatin/10 mg ezetimibe to those of 20 mg rosuvastatin. Materials and Methods A literature search was conducted using the PubMed, EMBASE, Cochrane, Web of Sciences, and SCOPUS databases up to December 2021. Human studies investigating the two aforementioned regimens with a randomized controlled design were selected. Outcome variables included the percentage reduction in LDL-C and other lipid parameters and rates of composite adverse events (AEs), including muscle-related symptoms. A random-effects meta-analysis was performed after heterogeneity testing between studies. Results Seven studies were included in this meta-analysis. The percentage LDL-C reduction did not differ between the combination and monotherapy groups [standardized mean difference (SMD) 0.08; 95% confidence interval (CI) -0.09 to 0.26; p=0.35]. The risk of composite AEs (odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the monotherapy group. The percentage of total cholesterol reduction was greater in the combination group (SMD 0.22; p=0.02), whereas that of triglyceride reduction and high-density lipoprotein cholesterol elevation did not differ between the two groups. Conclusion This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anticholesteremic Agents* / adverse effects | - |
dc.subject.MESH | Cholesterol, LDL / therapeutic use | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Ezetimibe / adverse effects | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects | - |
dc.subject.MESH | Hypercholesterolemia* / drug therapy | - |
dc.subject.MESH | Rosuvastatin Calcium / therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yura Kang | - |
dc.contributor.googleauthor | Jung Mi Park | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.identifier.doi | 10.3349/ymj.2023.0285 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 38154476 | - |
dc.subject.keyword | Hypercholesterolemia | - |
dc.subject.keyword | drug therapy | - |
dc.subject.keyword | hydroxymethylglutary-CoA reductase inhibitors | - |
dc.subject.keyword | preventive medicine | - |
dc.contributor.alternativeName | Lee, Snag Hak | - |
dc.contributor.affiliatedAuthor | 이상학 | - |
dc.citation.volume | 65 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 19 | - |
dc.citation.endPage | 26 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.65(1) : 19-26, 2024-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.